References 1. Isaza MP, Chau JT, Le A, Balashova NV, Patel JK, et al. (2008) A bioluminescent HL-60 cell line to assay anti-leukemia therapeutics under physiological conditions. Luminescence 23(1): 17–21. 2. McCormack E, Micklem DR, Pindard LE, Siden E, Gallant P, et al. (2007) In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time domain autofluorescence decoupling, fluorohore quantification, and localization. Mol Imaging 6(3): 193–204. 3. Ghoroghchian PP, Therien MJ, Hammer DA (2009) In vivo fluorescence: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(2): 156–167. 4. Leblond F, Davis SC, Valde´s PA, Pogue BW (2010) Pre-clinical whole body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol 98(1): 77–94. 5. Krause DS, Spitzer TR, Stowell CP (2010) The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. Arch Pathol Lab Med 134(7): 1033–1038. 6. Goodison S, Urquidi V, Tarin D (1999) CD44 cell adhesion molecules. J Clin Pathol 52: 189–196. 7. Omary MB, Trowbridge IS, Battifora HA (1980) Human homologue of murine T200 glycoprotein. J Exp Med 152: 842–852. 8. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906–4912. 9. Morris JC, Waldmann TA (2009) Antibody-based therapy of leukemia. Expert Rev Mol Med 30: 11–29. 10. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, et al. (2009) Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 114(6): 1226–1235. 11. Kotzerke J, Bunjes D, Scheinberg DA (2005) Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant 36(12): 1021–1026. 12. Cre´ancier L, Menon Y, Pillon A, Verdier J, Chansard N, et al. (2010) Monitoring of tumor progression in orthotopic AML mouse models using quantitative RT-PCR and/or bioluminescence imaging: Application to the targeted cytotoxic agent F14512. Proc Am Assoc Cancer Res Abst 406:101st. Washington: Annual Meeting. Optical Imaging of Leukemia 13. Kalchenko V, Shivtiel S, Malina V, Lapid K, Haramati S, et al. (2006) Use of lipophilic near-infrared dye in whole-body optical imaging of hematopietic cell homing. J Biomed Opt 11(5): 1–3. 14. Leners N, Ferrant A, Jamar F (1991) Evaluation of two 111In-oxinate formulations for labelling of white blood cells. Int J Rad Appl Instrum B 18: 727–733. 15. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, et al. (2002) Ex vivo cell labeling with 64Cu–pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imag- ing cell trafficking in mice with positron-emission tomography. PNAS 99(5): 3030–3035. 16. Kuenzle K, Taverna C, Steinert HC (2002) Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose. Mol Imaging Biol 4(2): 179–183. 17. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, et al. (2010) Utility of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 24(3): 613–620. 18. Olafsen T, Wu AM (2010) Antibody vectors for imaging. Semin Nucl Med 40(3): 167–181. 19. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, et al. (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyannatobenzyl-desferrioxamine. Nat Protoc 5(4): 739–743. 20. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, et al. (2004) Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 3(2): 117–124. 21. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic- pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16): 3765–3772. 22. Liu J, Jiang G (2006) CD44 and hematologic malignancies. Cell Mol Immunol 3(5): 359–365. 23. Burke JM, Jursic JG, Scheinberg DA (2002) Radioimmunotherapy for acute leukemia. Cancer Control 9: 106–113. 24. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, et al. (2009) A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23: 2109–2117. PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30690